[go: up one dir, main page]

PE20060276A1 - Composiciones que contienen policosanol, niaciana y/o derivados de niacina - Google Patents

Composiciones que contienen policosanol, niaciana y/o derivados de niacina

Info

Publication number
PE20060276A1
PE20060276A1 PE2005000581A PE2005000581A PE20060276A1 PE 20060276 A1 PE20060276 A1 PE 20060276A1 PE 2005000581 A PE2005000581 A PE 2005000581A PE 2005000581 A PE2005000581 A PE 2005000581A PE 20060276 A1 PE20060276 A1 PE 20060276A1
Authority
PE
Peru
Prior art keywords
depression
acid
policosanol
niacin
docicosanol
Prior art date
Application number
PE2005000581A
Other languages
English (en)
Inventor
Roger Berlin
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20060276A1 publication Critical patent/PE20060276A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA EN FORMA DE TABLETA, CAPSULA, LIQUIDO O POLVO QUE COMPRENDE: A) POLICOSANOL EL CUAL ES UNA MEZCLA DE ALCOHOLES ALIFATICOS PRIMARIOS DE CADENA RECTA DE 20-36 CARBONOS DE LONGITUD TALES COMO 1-EICOSANOL, 1-DOCOSANOL, 1-HEPTACOSANOL, 1-TRIACONTANOL, ENTRE OTROS; B) NIACINA SELECCIONADO ENTRE ACIDO NICOTINICO, ACIPIMOX (ACIDO 5-METILPIRACINOCARBOXILICO, 4-OXIDO), NICOTINATO DE ALUMINIO, NICERITROL (ESTER DE ACIDO 3-PIRIDINOCARBOXILICO 2,2-BIS[[3-PIRIDINILCARBONIL]OXI]METIL)-1,3-PROPANODIIL, NICOCLONATO, INOSITOL HEXANIACINATO, ENTRE OTROS. DICHA COMPOSICION TIENE UNA PROPORCION CUANTITATIVA POLICOSANOL/NIACINA DE 3:1 A 0,33:1 POR PESO; PERMITIENDO DISMINUIR Y MANTENER SIGNIFICATIVAMENTE NIVELES SALUDABLES DE COLESTEROL EN LA SANGRE, UTILES EN EL TRATAMIENTO DE HIPERCOLESTEROLEMIA, ENFERMEDADES INMUNOREGULADORAS, ENFERMEDADES CARDIOVASCULARES, DEPRESION Y/O DESORDENES NEURODEGENERATIVOS, ENTRE OTROS
PE2005000581A 2004-05-25 2005-05-25 Composiciones que contienen policosanol, niaciana y/o derivados de niacina PE20060276A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/853,735 US20050267091A1 (en) 2004-05-25 2004-05-25 Compositions containing policosanol and niacin and/or niacin derivatives and their pharmaceutical uses

Publications (1)

Publication Number Publication Date
PE20060276A1 true PE20060276A1 (es) 2006-05-12

Family

ID=35426169

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000581A PE20060276A1 (es) 2004-05-25 2005-05-25 Composiciones que contienen policosanol, niaciana y/o derivados de niacina

Country Status (4)

Country Link
US (1) US20050267091A1 (es)
PE (1) PE20060276A1 (es)
TW (1) TW200603784A (es)
WO (1) WO2005115390A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879375B1 (en) * 2006-06-23 2011-02-01 Arizona Pharmaceuticals, LLC Pharmaceutical composition
WO2008101956A1 (de) * 2007-02-23 2008-08-28 Basf Se Gemische von n-alkanolen und ihre verwendung
MX2009009126A (es) * 2007-03-01 2009-10-28 Concourse Health Sciences Llc Isomeros de niacinato de inositol y usos de los mismos.
EP1992235A1 (en) * 2007-05-09 2008-11-19 Health Concern B.V. Premix for cholesterol lowering food products
US8404275B2 (en) * 2007-07-01 2013-03-26 Vitalis Llc Combination tablet with chewable outer layer
WO2009033078A2 (en) * 2007-09-05 2009-03-12 Raif Tawakol Compositions and methods for controlling cholesterol levels
JP5711671B2 (ja) * 2009-02-23 2015-05-07 ナノルクス、インコーポレイテッドＮａｎｏｒｘ，Ｉｎｃ． ポリコサノールナノ粒子
USRE46608E1 (en) 2009-09-01 2017-11-14 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
RU2569063C2 (ru) 2009-09-01 2015-11-20 Катабэйсис Фармасьютикалз, Инк. Конъюгаты жирных кислот и ниацина и их применение
WO2012027159A1 (en) 2010-08-23 2012-03-01 NanoRx, Inc. Policosanol nanoparticles
US9226891B2 (en) 2011-10-28 2016-01-05 Vitalis Llc Anti-flush compositions
AU2013266087A1 (en) * 2012-05-25 2014-12-04 Catabasis Pharmaceuticals, Inc. Methods of lowering proprotein convertase subtilisin/kexin type 9 (PCSK9)
KR101492213B1 (ko) * 2012-10-30 2015-02-16 한국식품연구원 폴리코사놀을 유효성분으로 하는 히스타민 수용체 길항제 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031376A (en) * 1956-10-11 1962-04-24 Levin Compositions comprising octacosanol, triacontanol, tetracosanol, or hexacosanol, andmethods employing same
US4623667A (en) * 1985-06-28 1986-11-18 Richardson-Vicks Inc. Topical treatment of skin inflammatory disorders
US4793991A (en) * 1986-01-31 1988-12-27 Slimak Karen M Hypoallergenic cosmetics, lip balms and lip sticks
US5166219A (en) * 1989-11-02 1992-11-24 Lidak Pharmaceuticals Systemic anti-inflammatory treatment
CU22229A1 (es) * 1992-09-29 1996-01-31 Dalmer Lab Sa Policosanol, una mezcla de alcoholes alifaticos primarios superiores para hipergregabilidad plaquetaria, los accidentes isquemicos, trombosis e incluso efectividad contra ulceras gastricas quimicamente inducidas y su proceso de obtencion de la caña de azucar. el tratamiento de complicaciones ateroscleroticas tales como la
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6596776B2 (en) * 1999-06-21 2003-07-22 Hauser, Inc. High molecular weight primary aliphatic alcohols obtained from natural products and uses thereof
MXPA02010184A (es) * 2000-04-14 2004-08-19 Niadyne Corp Formulaciones topicas para el suministro transdermico de niacina y metodos para tratar hiperlipidemia.
DE60132523T2 (de) * 2000-08-03 2008-04-30 Härting, Thomas Francis Pharmazeutische- und Nahrungsmittelzusammensetzungen mit "Holzalkohol" und "Holzsterol" zur Senkung des Serumcholesterins
SE0003907D0 (sv) * 2000-10-27 2000-10-27 Swe Dencare Komposition för eliminering av tandsten ur munnen
US20050002992A1 (en) * 2003-06-17 2005-01-06 Mccleary Edward Larry Foods, beverages, condiments, spices and salad dressings with specialized supplements
US6436431B1 (en) * 2001-07-02 2002-08-20 Diane Wright Hoffpauer Fortified rice bran food product and method for promoting cardiovascular health
EP1487489A4 (en) * 2002-03-04 2008-10-01 Medimmune Inc METHOD FOR PREVENTING OR TREATING ILLNESSES BY ADMINISTERING AN INTEGRIN AVB3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE
US20030203854A1 (en) * 2002-04-23 2003-10-30 Ivo Pischel Composition for effecting serum cholesterol levels
US20050085454A1 (en) * 2003-10-16 2005-04-21 Natreon Inc. Phenolic antioxidant-chromium complexes for treatment or prevention of type 2 diabetes or glucose intolerance
US20060025486A1 (en) * 2004-07-27 2006-02-02 Roger Berlin Compositions containing policosanol and B vitamins and their pharmaceutical uses

Also Published As

Publication number Publication date
TW200603784A (en) 2006-02-01
WO2005115390A2 (en) 2005-12-08
WO2005115390A3 (en) 2007-04-26
US20050267091A1 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
PE20060276A1 (es) Composiciones que contienen policosanol, niaciana y/o derivados de niacina
PE20050128A1 (es) Formulacion farmaceutica
AR071187A1 (es) Compuesto de arilmetil-tiazinamina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento de la enfermedad de alzheimer
NZ743706A (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
PE20091461A1 (es) Forma de dosificacion farmaceutica para la administracion oral de inhibidor de tirosina quinasa
BRPI0510297A (pt) método para produir um carbonato de dialquila e um diol, e, carbonato de dialquila
AR082930A1 (es) Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina
PH12017501328B1 (en) Self-emulsifying composition of ?-3 fatty acid
BR112015004185A2 (pt) composições antiperspirantes em aerossol, produtos e métodos
AR102198A1 (es) Proceso para reducir partículas subvisibles en una formulación farmacéutica
RU2007101519A (ru) Композиция в форме спрея, содержащая в масляной фазе сочетание кортикоида и производного витамина d
AR074391A1 (es) Composicion farmaceutica de un potente inhibidor de hcv para su administracion oral
EA200970841A1 (ru) Фармацевтическое применение замещенных амидов
EA200700924A1 (ru) Соединения ряда дибензиламина и их производные
WO2006033948A3 (en) Sustained local anesthetic composition containing preferably a sugar ester such as saib
RU2017139767A (ru) Концентрированные терапевтические фосфолипидные композиции
Liang et al. Syntheses, biological evaluation and SAR of ingenol mebutate analogues for treatment of actinic keratosis and non-melanoma skin cancer
BR112012029961A2 (pt) compostos de carbamato de ciclo-exila como ativos de clareamento da pele e/ou cabelo
RU2013148812A (ru) Косметическая композиция, включающая 4-(3-этокси-4-гидроксифенил)-2-бутанон и липофильный растворитель
NZ631833A (en) Emulsion formulations
PE20060465A1 (es) Composiciones que contienen policosanol y un inhibidor de reductasa hmg-coa
Chen et al. Design, synthesis and antioxidant activity evaluation of novel β-elemene derivatives
Liu et al. Design, synthesis and cytotoxic activity of novel spin-labeled rotenone derivatives
EA200700130A1 (ru) Композиции, содержащие стронций и витамин d, и их применение
DK1383756T3 (da) Cumarinderivater til anvendelse som antikoagulanter

Legal Events

Date Code Title Description
FD Application declared void or lapsed